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SUMMARY
Periodic limb movements in sleep (PLMS) is prevalent among dialysed
patients and is associatedwith increased risk of mortality. Our study aimed
to determine the prevalence of this disease in a sample of transplanted and
waiting-list haemodialysed patients. One hundred transplanted and 50
waiting-list patients underwent polysomnography. Moderate and severe
diseases were defined as periodic limbmovements in sleep index (PLMSI)
higher than 15 and 25 events h)1, respectively. The 10-year coronary heart
disease risk was estimated for all patients using the Framingham Score.
Moreover, the 10-year estimated risk of stroke was calculated according to
the modified version of the Framingham Stroke Risk Profile. PLMS was
present in 27% of the transplanted and 42% of the waiting-list group
(P = 0.094); the proportion of severe disease was twice as high in waiting-
list versus transplanted patients (32 versus 16%,P = 0.024). Patients with
severe disease had a higher 10-year estimated risk of stroke in the
transplanted group [10 (7–17) versus 5 (4–10);P = 0.002] and a higher 10-
year coronary heart disease risk in both the transplanted [18 (8–22) versus
7 (4–14); P = 0.002], and the waiting-list groups [11 (5–18) versus 4 (1–9);
P = 0.032]. In multivariable linear regression models the PLMSI was
associated independently with the Framingham cardiovascular and
cerebrovascular scores after adjusting for important covariables. Higher
PLMSI is an independent predictor of higher cardiovascular and cerebro-
vascular risk score in patientswith chronic kidneydisease.SeverePLMS is
less frequent in kidney transplant recipients compared to waiting-list
dialysis patients.
INTRODUCTION
Periodic limb movements in sleep (PLMS) is a repetitive
periodic activity of the anterior tibial muscle resulting in the
movement of the big toe and ⁄or ankle. Occasionally, flexion
of the knee or the hip can also occur. Polysomnography
studies have confirmed that these limb movements are often
associated with electroencephalographic arousals, which can
lead to worse subjective and objective sleep quality and may
cause impaired daytime functioning, fatigue and sleepiness.
PLMS is common in chronic kidney disease Stage 5
dialysed (CKD5D) patients, with an estimated prevalence of
40–70% among patients on maintenance dialysis (Hanly
et al., 2003; Jurado-Gamez et al., 2007; Rijsman et al., 2004)
compared to 7–8% in the general population. The Periodic
Limb Movement Index (PLMI), i.e. the number of periodic
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limb movements per hours during sleep, is higher in
haemodialysed compared to the general population, and it
is often in the moderate–severe range (Beecroft et al., 2008;
Jurado-Gamez et al., 2007; Parker et al., 2005). The only
published paper which assessed periodic limb movement
before and after transplantation in 18 CKD5T (CKD5 trans-
planted, Tx) reported that PLMI was reduced significantly
(Beecroft et al., 2008).
It has been suggested that PLMS is associated with
increased cardiovascular risk in the general population
(Walters and Rye, 2009). Studies have shown an association
between PLMS and hypertension as well as congestive heart
failure (Hanly and Zuberi-Khokhar, 1996; Javaheri, 2006;
Skomro et al., 2009). One possible explanation of this
observation is the repetitive sympathetic activation accom-
panying the PLM events which usually manifest in increased
heart rate (Ferrillo et al., 2004; Sforza et al., 1999; Winkel-
man, 1999) and blood pressure (Allena et al., 2009; Penne-
stri et al., 2007). The repetitive, long-standing nocturnal
sympathetic hyperactivity may, in turn, lead to daytime
hypertension. Furthermore, PLMS often accompanies
chronic illnesses [e.g. diabetes and renal failure (Hanly and
Zuberi-Khokhar, 1996; Jurado-Gamez et al., 2007; Rijsman
et al., 2004)] which increase cardiovascular risk (Walters and
Rye, 2009). PLMS is associated with obstructive sleep
apnoea (OSA), which has also been linked to cardiovascular
morbidity and mortality, both in the general population
(Young et al., 2008) and in haemodialysed and Tx patients
(Masuda et al., 2011; Molnar et al., 2010).
To date, only two studies have examined the association
between mortality and PLMS among dialysed patients. Benz
et al. found that the 20-month survival rate among patients
with PLMI <20 was >90% versus 50% among patients with
PLMI 20 or higher (Benz et al., 2000). In accord with previous
data, higher PLMI predicted mortality during a 48-month-long
follow-up in a recent cohort study (Jung et al., 2010). To
examine potential confounding, in both studies Cox regres-
sion models were applied that included PLMI and one
potential confounder at a time, but to date we are not aware
of any published study which would have assessed the
association between PLMS and cardiovascular risk or mor-
tality using multivariable models, adjusting for multiple clinical
and biochemical variables.
Only limited data have been published about the associ-
ation between PLMS and stroke. Several case reports have
described the occurrence of PLMS after cerebrovascular
events, but no data have been published about the prospec-
tive association of PLMS and stroke. Extrapolation of the
published results may suggest a relationship between PLMS
versus stroke; however, studies are needed to analyse this
potential relationship in detail.
We designed this cross-sectional analysis to examine the
association between PLMS and cardio- and cardiovascular
risk. Our primary hypothesis was that the presence of PLMS
is associated with an increased estimated cardio- and
cardiovascular risk both in waitlisted hemodialysis (WL) and
Tx groups. To analyse the association between these factors,
we built multivariable linear regression models to adjust for
the most important covariables related to cardio- and cardio-
vascular risk. Our study is the first to use this approach and to
control for a large number of potential confounders in order to
assess the independent association between PLMS versus
the risk of cardiovascular disease and stroke. Furthermore,
we determined the prevalence and clinical correlates of
PLMS using polysomnography in a sample of stable
prevalent Tx patients and a convenience sample of waiting-
list dialysed patients (WL). Based on previous reports
(Beecroft et al., 2008), we hypothesized that the prevalence
of PLMS would be lower in Tx versus WL patients.
METHODS
Sample of patients and data collection
For this study [SLeep disorders Evaluation in Patients after
kidney Transplantation (SLEPT)], potentially eligible patients
were selected from all prevalent adult Tx patients (total clinic
population; n = 1214) who were followed regularly at a single
outpatient transplant centre on 31 December 2006. After
applying exclusion criteria [previous diagnosis of OSA or
PLMS, recent (<3 months) start of dialysis or transplantation,
active and acute respiratory disorder, acute infection, hospi-
talization within 1 month, surgery within 3 months], 1198
patients remained (base population; n = 1 198) eligible for
enrolment. From this base population we randomly selected
and approached 150 patients (Tx study sample) using the
simple random sampling strategy offered by spss version
15.0 (IBM Corporation, Armonk, New York, USA) (Fig. S1).
We asked all (n = 100) eligible WL dialysis patients who were
treated at the four largest dialysis centres in Budapest (listed
with the above transplant centre) to participate (WL study
sample). Details of medical history such as age, gender, level
of education, smoking and aetiology and history of CKD were
collected at enrolment.
The primary aim of our study was to assess the association
between prevalence of severe PLMI and cardiovascular and
stroke risk in our WL and Tx patients. For sample size
calculation we used the data of WL and Tx patients with
PLMI < 25 h)1. We hypothesized that the calculated risk
would be twice as high in patients with PLMI ‡ 25 h)1. We
assessed the sample size for WL and Tx patients as 30, 56
for cardiovascular risk and 30 and 79 for stroke risk,
respectively.
Our secondary aim was to assess the type of renal
replacement therapy associated with presence of severe
PLMI in our end-stage renal disease (ESRD) population.
Based on previous data we hypothesized that the prevalence
of severe PLMI would be 40% in WL haemodialysis patients
(Hanly et al., 2003; Jurado-Gamez et al., 2007; Rijsman
et al., 2004) and the difference between the two groups was
25%, for which power calculation was performed (n = 53 for
WL and 79 for Tx patients). Based on the above-mentioned
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calculations, our aim was to include at least 150 Tx patients
and 100 WL patients, because we expected a refusal rate of
50%.
Laboratory data
Laboratory data [haemoglobin (Hb), C-reactive protein
(CRP), intact parathormone (iPTH), serum creatinine, blood
urea nitrogen (BUN), serum albumin, serum cholesterol,
serum triglyceride, serum high-density lipoprotein (HDL) and
low-density lipoprotein (LDL) cholesterol] and single pool (sp)
Kt ⁄V (spKt ⁄V) were extracted from the medical records.
Estimated glomerular filtration rate (eGFR) was calculated
using the abbreviated Modification of Diet in Renal Disease
(MDRD) study formula.
Comorbidity
Comorbidity was assessed by the modified Charlson Com-
orbidity Index (CCI) (Hemmelgarn et al., 2003; Jassal et al.,
2005), completed by the most responsible transplant physi-
cian. We also collected data about coronary disease and
hypertension from the medical records. Atrial fibrillation was
diagnosed from the electrocardiogram (ECG) recorded dur-
ing polysomnography.
Polysomnography
Standard, attended overnight polysomnography was per-
formed in the sleep laboratory at the 1st Department of
Internal Medicine, Semmelweis University (SOMNOscreen
TM
PSG Tele, CE0494; SOMNOmedics GmBH, Germany). The
recordings were scored manually by two somnologists
(M.Z.M., A.L.). Sleep stages were determined in 30-s epochs
according to Rechtschaffen and Kales.
Definition and classification of PLMS
PLMS was defined by the following criteria: limb movement
(LM) duration: 0.5–5 s; inter-movement interval: 5–90 s; and
separation criteria for LMsoccurring in both legs:more than 5 s
between onsets. At least four LMs were included in one PLMS
cycle (Walters et al., 2007). The PLMI was defined as the
number of limb movements per hours during sleep. The
patientswith PLMSwere divided into two categories of severity
of PLMS: moderate: 15£ PLMI <25 and severe: PLMI ‡25.
The cut-off point of 25 was reported to be clinically relevant in
several studies (Rijsman et al., 2004; Skomro et al., 2009).
Respiratory related movements were excluded from the PLMI
count.
Definition of obstructive sleep apnoea
Apnoea was defined as the absence of airflow for more than
10 s; hypopnoea was defined as a clearly discernible
reduction in airflow for more than 10 s associated with an
arousal and ⁄or reduction in oxygen saturation by >3%. The
apnoea–hypopnoea index (AHI) was defined as the number
of apnoeas and hypopnoeas per 1 h)1 of sleep (American
Academy of Sleep Medicine, 1999).
Transplantation- and donor-related data;
immunosuppressive therapy
Transplantation-related information included current medica-
tions, transplant and dialysis vintage (i.e. time elapsed since
transplantation or since the initiation of dialysis treatment),
time spent on dialysis prior to transplantation, type of
transplantation (deceased or living donor), history of acute
rejection, human leucocyte antigen (HLA) mismatch, pre-
transplant panel reactive antibodies titre (PRA), cold ischae-
mic time (CIT) and age and gender of donor and history of
delayed graft function. Time elapsed since the initiation of
the first treatment for end-stage renal disease (ESRD)
(cumulative ESRD time) was also calculated. Standard
maintenance immunosuppressive therapy generally con-
sisted of calcineurin inhibitor: cyclosporin A microemulsion
formulation (CsA) or tacrolimus; combined with mycophen-
olate-mofetil (MMF); or azathioprine, prednisolone, everoli-
mus or sirolimus.
Framingham risk scores and blood pressure
measurement
The 10-year coronary heart disease risk was estimated for all
patients using the Framingham score (calculated with LDL-
cholesterol) (Wilson et al., 1998). Similarly, the 10-year
estimated risk of stroke was calculated according to the
modified version of the Framingham Stroke Risk Profile
(DAgostino et al., 1994).
The Framingham Heart Study is a prospective epidemio-
logical cohort study. Subjects returned to the study every
2 years for a detailed medical history, physical examination
and laboratory tests. Factors for age, gender, cigarette
smoking, blood cholesterol, HDL and LDL cholesterol, blood
pressure, left ventricular hypertrophy and diabetes mellitus
have been analysed in the Framingham Heart Study for the
creation of a model for coronary heart disease (CHD)
prediction. Subjects receive a point score based on categor-
ical values of age, total cholesterol, HDL cholesterol, blood
pressure, smoking and diabetes.
The Framingham Stroke Risk Profile is based on the
following risk factors: age, systolic blood pressure, antihy-
pertensive medication, diabetes, cigarette smoking status,
history of cardiovascular disease, atrial fibrillation and left
ventricular hypertrophy as determined by ECG. Score sheets
were developed for prediction of CHD and stroke risk were
developed from the b-coefficients of Cox proportional hazard
models, which includes the above-mentioned variables. Point
scores are assigned to percentage values which show the
risk of coronary heart disease and stroke. We used these
percentage values in our analyses.
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Ethical approval
The study was approved by the Ethics Committee of the
Semmelweis University (4 ⁄2007). Patients received detailed
verbal and written information about the aims and protocol of
the study before enrolment, and signed an informed consent.
Statistical analysis
Statistical analyses were carried out using SPSS version 15.0
software. Results are presented as percentage, mean ±
standard deviation (SD) or medians (interquartile range:
IQR). Continuous variables were compared between WL
versus Tx recipient patients, and also between patients with
versus without severe PLMS, using Students t-test or the
Mann–Whitney U-test. Categorical variables were analysed
with the chi-square test. Spearmans correlation was used to
assess the association between PLMI versus continuous
variables. To identify factors which were associated indepen-
dently with the presence of severe PLMS, a logistic regression
model was built. The variables entered in the multivariable-
adjusted models were selected by theoretical considerations;
we included predictors in the models which were known to be
associated with PLMS based on external evidence and
clinical experience, and which were available in our database.
Linear associations between PLMI and Framingham risk
score were assessed using fractional polynomials and
restricted cubic splines. To assess if PLMI is associated
independently with the Framingham risk scores, multivariable
linear regression models were built. The variables entered
into the multivariable-adjusted models were selected by
theoretical considerations; we included predictors in the
models which, based on external evidence and clinical
experience, were known to be associated with elevated
cardiovascular risk and which were available in our database.
The risk scores were transformed logarithmically to obtain
normal distribution. Variance inflation factors (VIF) were used
to indicate collinearity between independent variables. Only
two-sided P-values were computed and the results were
considered statistically significant if P was < 0.05.
RESULTS
Demographic data and baseline characteristics of the
sample
Of the 250 eligible patients (Tx study sample + WL study
sample, see Methods); 100 individuals, including 50 Tx (33%)
and 50 WL (50%) subjects, declined to participate. Conse-
quently, the final study sample included 100 Tx and 50 WL
patients (participants) (Fig. S1). Three WL patients were
treated with continuous ambulatory peritoneal dialysis and 47
WL patients with intermittent in-centre haemodialysis. There
were no significant differences regarding age and gender
between participants and those who declined to participate
(not shown). The basic characteristics (age, gender, eGFR,
haemoglobin, serum albumin) of the 100 participating Tx
patients (Tx study sample) were similar to the characteristics
of the total clinic population (not shown).
Baseline characteristics of the Tx and WL patients are
shown in Table 1. The two patient groups were similar along
most of the parameters analysed. Additionally, we have
created subgroups based on GFR of Tx patients and
examined baseline characteristics (see Table S1). Six per
cent (n = 3) of WL patients and 1% (n = 1) of Tx patients
were taking hypnotics. None of the enrolled patients was
treated with dopaminergic agents.
Prevalence and severity of periodic limb movement
is sleep in Tx versus WL dialysis patients
The PLMI was similar in the Tx and WL groups (median; IQR:
6.2 (0.7–16) versus 6.2 (0.8–45.1); P = 0.23). According to
the previously defined criteria, 27% of the Tx and 42% of WL
patients had PLMS (PLMI ‡15) (P = 0.094). The prevalence
of moderate PLMS was 11% in the Tx group and 10% in the
WL group. The proportion of severe PLMS, however, was
significantly higher among WL (32%) versus Tx (16%)
patients (P = 0.034) (Fig. 1).
Correlates of severe PLMS in the transplanted group
The percentage of males and microarousal index were higher
among patients with severe PLMS (PLMI ‡25). No other
difference regarding sociodemographic, anthropometric and
sleep characteristics was observed between patients with
and without severe PLMS (Table 2).
Forty-three per cent of the Tx patients had OSA (AHI ‡5).
PLMI correlated weekly with AHI (Spearmans rho = 0.193;
P = 0.054), and median AHI appeared to be higher in the
group with severe PLMS; however, this difference did not
reach statistical significance (median; IQR: 7.6 (2.1–23)
versus 2.6 (0.6–13.4); P = 0.137).
Correlates of severe PLMS in the dialysed group
Patients with severe PLMS had higher BMI, higher serum
triglyceride and LDL levels and the prevalence of iron
deficiency was also higher (Table 3).
The prevalence of OSA (AHI ‡5) in the WL patient group
was 54%. There was no significant correlation between PLMI
and AHI (Spearmans rho = 0.210; P = 0.143) in the WL
group, and similarly there was no difference in AHI between
patients with and without severe PLMS (median; IQR: 7.4
(1.6–21) versus 2.6 (0.8–11.8); P = 0.429).
Multivariable analysis
Logistic regression analysis was used to determine the
independent associations between severe PLMS and the
following variables: type of renal replacement therapy, age,
gender, presence of diabetes, presence of iron deficiency, AHI
and smoking. In this model the type of renal replacement
therapy (dialysis versus transplant) was an independent
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predictor of severe PLMS in addition to smoking, male gender
and age (Table 4).
Estimated coronary heart disease risk and
estimated stroke risk
The 10-year estimated coronary heart disease risk [based on
the Framingham score (Wilson et al., 1998)] and the 10-year
estimated stroke risk [based on the modified Framingham
stroke risk profile (DAgostino et al., 1994)] were twofold
higher in the severe PLMS group compared to patients
without severe PLMS (Table 2) in the Tx group. Both the
estimated coronary heart disease (CHD) risk and the
estimated stroke risk showed a moderate positive correlation
with PLMI (Spearmans rho = 0.265; P = 0.009 for CHD and
rho= 0.274; P = 0.006 for stroke).
Similarly, the estimated 10-year CHD risk was higher in
patients with severe PLMS (Table 3), and correlated
significantly with the PLMI (Spearmans rho = 0.409;
P = 0.022) in the WL group. The estimated stroke risk,
however, was not associated with the PLMI in this group
(not shown).
We assessed the association between Framingham
scores and PLMI using restricted cubic splines, which
disclose very close similarity between the Tx and the WL
groups regarding the association of logarithm of Framing-
ham cardio- and cardiovascular risk scores versus PLMI
(Fig. 2). These analyses reveal a similar, linearly increasing,
dose–response relationship between the PLMI and the risk
scores in both groups.
To assess the independent association between the PLMI
versus the Framingham CHD score a linear regression model
was built for the total sample (Tx + WL) and Tx as well as WL
11
10
16
32
58
73
0%
100%
Transplanted group Waitlisted dialyzed
group
no PLMS moderate PLMS severe PLMS
Figure 1. Presence of periodic limb movements in sleep (PLMS) in
transplanted group and waiting-list dialysed group.
Table 1 Patient characteristics
Transplanted (Tx)
patients (n = 100)
Waiting-list (WL)
patients (n = 50) P-value
PLMI (events h)1) (median; IQR) 6.2 (0.7–16) 6.2 (0.8–46) 0.230
Presence of PLMS (%) 27 42 0.094
Male (%) 57 54 0.731
Age (mean±SD) (years) 51 ± 13 50 ± 13 0.599
Level of education (%)
Primary education or less 21 14 0.213
Skilled workers 15 18
High school or equivalent 33 48
university diploma 31 20
Current smoker (%) 20 20 1
BMI (mean ± SD) (kg m)2) 27 ± 5 25 ± 4 0.058
Ferritin (median; IQR) (ng mL)1) 196 (74–378) 742 (257–800) <0.001
Iron deficiency (TSAT <20% and ⁄ or ferritin < 100 lg L)1) (%) 40 25 0.110
Prevalence of hypertension (%) 92 80 0.034
Prevalence of diabetes (%) 19 16 0.822
Charlson Comorbidity Index (median; IQR) 2 (2–3) 3 (2–5) 0.001
Haemoglobin (mean ± SD) (g L)1) 135 ± 17 116 ± 15 <0.001
Serum albumin (mean ± SD) (g L)1) 40 ± 3 42 ± 4 0.011
Serum CRP (median; IQR) (mg L)1) 3.4 (1.4–6) 2.2 (0.7–0.3) 0.417
eGFR (mean±SD) (mL min 1.73 m)2) 52 ± 19 NA –
spKt ⁄V (mean ± SD) NA 1.43 ± 0.24 –
Transplant or dialysis vintage (median; IQR) (months) 66 (30–113) 34 (16–57) NA
Cumulative ESRD time (median; IQR) (months) 99 (57–152) 50 (17.5–83.5) <0.001
Hypnotic drugs (%) 17 22 0.108
Framingham stroke risk (median; IQR) (%) 6 (4–11) 2 (3–10) 0.144
Framingham coronary heart disease based on LDL (median; IQR) (%) 8 (4–15) 5 (2–11) 0.035
PLMI, Periodic Limb Movement in Sleep Index; PLMS, periodic limb movement in sleep; BMI, body mass index; TSAT, transferrin saturation;
ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; SD, standard deviation; NA, not available; IQR, interquartile
range; CRP, C-reactive protein; LDL, low-density lipoprotein; spKTV, single pool (sp) Kt ⁄V.
PLMS in ESRD 301
 2011 European Sleep Research Society
separately (Tables 5–7). In the model for the total sample the
PLMI was associated independently with log-transformed
Framingham CHD score (b = 0.222; P = 0.004; Table 5). In
the WL group PLMI showed a similarly strong relationship
with Framingham CHD score (b = 0.357; P = 0.015,
Table 6); in the Tx group the model disclosed a clear trend
between two variables (b = 0.157; P = 0.090; Table 7).
In the similar linear regression model in the total sample
the PLMI was also associated significantly with the log-
transformed Framingham stroke risk score, even after
adjusting for the above-mentioned covariables (b = 0.154;
P = 0.031; Table S2). In WL patients PLMI is related to
Framingham stroke risk score (b = 0.312; P = 0.033;
Table S3), but in the Tx group did not reach statistical
significance (b = 0.098; P = 0.234; Table S4).
We assessed the potential interaction of treatment
modality (i.e. dialysis or transplantation) on the association
between PLMI versus the risk scores to examine whether
the two groups can be combined for the above-mentioned
analysis, and no interactions were detected (P-value for
the interaction term was P = 0.333 for Framingham cardio-
vascular risk and P = 0.106 for Framingham stroke risk).
DISCUSSION
Our study is the first, to our knowledge, to analyse the
complex association between PLMS and cardio- and cardio-
vascular disease in a relatively large sample of WT haemo-
dialysed and kidney transplanted patients using standard
polysomnography. Importantly, we found that PLMS is
associated independently with increased estimated cardio-
and cardiovascular risk in these populations, albeit in the Tx
population a clear trend can be recognized principally. The
point estimate suggests an association, and it is likely that
with more patients the associations would have been
significant. The apparent lack of association between PLMI
and cardio- and cardiovascular risk in the Tx group could also
be explained, in part, by the relatively fewer severe PLMS
cases in this group. We placed great emphasis on building
multivariable linear regression models to demonstrate that
Table 2 Patients with and without severe periodic limb movements in sleep (PLMS) in the transplanted group
PLMI<25 (n = 84) Severe PLMS (PLMI ‡ 25) (n = 16)
Age (mean ± SD) (years) 50 ± 13 55 ± 9 0.138
BMI (mean ± SD) (kg m)2) 26 ± 5 27 ± 4 0.450
Male (%) 50 94 0.001
Transplant vintage (median; IQR) (months) 76 (30–118) 50 (30–98) 0.384
Albumin (mean ± SD) (g L)1) 40 ± 3 39 ± 3 0.611
Presence of diabetes (%) 15 37 0.075
Haemoglobin (mean ± SD) (g L)1) 134 ± 17 137 ± 15 0.494
Iron deficiency (TSAT <20% and ⁄ or
ferritin < 100 lg L)1) (%)
38 53 0.392
eGFR (mean ± SD) (mL min 1.73 m)2) 53 ± 18 48 ± 21 0.358
Hypertension (%) 93 87 0.611
Current smoker (%) 19 25 0.733
Charlson comorbidity index (median; IQR) 2 (2–3) 2 (2–3) 0.404
Prevalence of coronary heart disease (%) 9 0 0.348
Prevalence of congestive heart failure (%) 9 0 0.348
Prevalence of peripheral vascular disease (%) 9 3 0.402
Prevalence of cerebrovascular disease (%) 2 0 1
Prevalence of atrial fibrillation (%) 2 6 0.411
Triglyceride (median; IQR) (mmol L)1) 1.6 (1.2–2.2) 2.2 (1.5–3) 0.076
LDL-cholesterol (median; IQR) (mmol L)1) 3.2 (2.7–3.7) 3.1 (2.6–3.4) 0.315
HDL-cholesterol (median; IQR) (mmol L)1) 1.4 (1.1–1.6) 1.1 (0.9–1.3) 0.017
Ferritin (median; IQR) (ng mL)1) 206 (75–411) 165 (72–334) 0.736
Framingham stroke risk (median; IQR) (%) 5 (4–10) 10 (7–17) 0.002
Framingham Coronary Heart Disease based
on LDL (median; IQR) (%)
7 (4–14) 18 (8–22) 0.002
Apnoea–hypopnoea index (event h)1) (median; IQR) 2.6 (0.6–13.4) 7.6 (2.1–23) 0.137
Microarousal index (event h)1) (median; IQR) 15 (9–23) 24 (15–41) 0.008
Percentage of Stage 1 (%) 9 (5–14) 12 (7–18) 0.089
Percentage of Stage 2 (%) 44 (33–53) 45 (30–43) 0.785
Percentage of deep sleep (%) 11 (7–18) 11 (5–16) 0.529
Percentage of REM (%) 12 (8–17) 14 (6–20) 0.446
Sleep efficiency (%) 80 (72–87) 82 (62–88) 0.292
Stage shift index (event h)1) (median; IQR) 18 (12–29) 19 (13–33) 0.888
PLMI, Periodic Limb Movement in Sleep Index; SD, standard deviation; BMI, body mass index; eGFR, estimated glomerular filtration rate;
IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein; REM, rapid eye movement.
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PLMS is independent predictor of cardio- and cardiovascular
risk even after adjusting for other important risk factors.
Although we clearly cannot claim causality between PLMS
and cardiovascular risk, together with the published evidence
our results contribute to the question of whether treating
PLMS successfully would reduce cardiovascular risk.
In our sample about one-third of the participants had
PLMS. The prevalence of severe PLMS was significantly
lower in Tx patients. Furthermore, we also demonstrated that
age, male gender, current smoking and dialysis treatment
(compared to transplant) are risk factors for PLMS in dialysed
and transplant patients.
Patients in our sample with severe PLMS had higher
estimated cardiovascular and cerebrovascular risk scores in
the Tx group and higher cardiovascular risk score in the WL
group compared to patients with lower PLMI. It has been
established previously that PLMS, even without microarou-
sals, leads to sympathetic activation and increased heart rate
variability. In addition, PLMS may contribute to diminish the
nocturnal dipping of blood pressure and pulse rate. This and
the sympathetic overactivity associated with PLMS may
contribute to the pathomechanism of cardiovascular and
cerebrovascular diseases. Potentially leading to transient
nocturnal rise of heart rate and arterial blood pressure, PLMS
may contribute to this association (Sforza et al., 1999).
Previously reported evidence suggests that patients with
PLMS have sympathetic overactivity during sleep (Ferrillo
et al., 2004). Due to this effect, long-term PLMS might be
associated with higher daytime blood pressure in the general
population (Espinar-Sierra et al., 1997). Patients with versus
without severe PLMS had similar blood pressure in our study.
A possible explanation for this could be the very high
prevalence of hypertension and the fact that the majority of
dialysed and Tx patients received antihypertensive treat-
ment.
Previous studies have repeatedly suggested an associa-
tion between PLMS and OSA. Thus, the well-known asso-
ciation between OSA and cardiovascular risk may contribute
to the relationship between PLMS and cardiovascular risk. In
our sample, however, there was only a weak correlation
Table 3 Patients with and without severe periodic limb movements in sleep (PLMS) in the dialysed group
PLMI<25 (n = 34) Severe PLMS (PLMI ‡ 25) (n = 16)
Age (mean ± SD) (years) 49 ± 14 53 ± 11 0.255
BMI (mean ± SD) (kg m)2) 24 ± 5 27 ± 5 0.045
Male (%) 47 69 0.225
Dialysis vintage (median; IQR) (months) 32 (16–57) 46 (14–63) 0.739
Albumin (mean ± SD) (g L)1) 42 ± 5 42 ± 3 0.516
Presence of diabetes (%) 9 31 0.092
Haemoglobin (mean ± SD) (g L)1) 115 ± 15 119 ± 13 0.300
Iron deficiency (TSAT <20% and ⁄ or
ferritin < 100 lg L)1) (%)
12 60 0.006
spKt ⁄V (median; IQR) 1.4 (1.2–1.7) 1.32 (1.2–1.5) 0.238
Hypertension (%) 77 88 0.468
Current smoker (%) 12 38 0.056
Charlson comorbidity index (median; IQR) 3 (2–4) 3 (2–5) 0.485
Prevalence of coronary heart disease (%) 15 25 0.442
Prevalence of congestive heart failure (%) 9 0 0.542
Prevalence of peripheral vascular disease (%) 15 19 0.699
Prevalence of cerebrovascular disease (%) 6 6 1
Prevalence of atrial fibrillation (%) 3 6 0.542
Triglyceride (median; IQR) (mmol L)1) 1.6 (0.9–2.3) 2.32 (1.6–3.2) 0.042
LDL-cholesterol (median; IQR) (mmol L)1) 1.8 (1.4–2.9) 3.14 (2.6–3.3) 0.015
HDL-cholesterol (median; IQR) (mmol L)1) 1.1 (1–1.2) 0.99 (0.9–1.2) 0.272
Ferritin (median; IQR) (ng mL)1) 796 (303–835) 310 (129–762) 0.078
Framingham stroke risk (median; IQR) (%) 5 (2–9) 6 (5–11) 0.173
Framingham Coronary heart disease based
on LDL (median; IQR) (%)
4 (1–9) 11 (5–18) 0.008
Apneoa–hypopnoea index (event h)1) (median; IQR) 2.6 (0.8–11.8) 7.4 (1.6–21) 0.429
Microarousal index (event h)1) (median; IQR) 21 (13–28) 22 (14–41) 0.382
Percentage of Stage 1 (%) 10 (8–14) 12 (7–18) 0.394
Percentage of Stage 2 (%) 36 (28–43) 38 (30–43) 0.533
Percentage of deep sleep (%) 13 (8–19) 11 (5–16) 0.253
Percentage of REM (%) 11 (7–17) 12 (6–20) 0.884
Sleep efficiency (%) 75 (66–84) 75 (62–88) 0.677
Stage shift index (event h)1) (median; IQR) 27 (21–30) 22 (13–33) 0.519
PLMI, Periodic Limb Movement in Sleep Index; IQR, interquartile range; REM, rapid eye movement; BMI, body mass index; SD, standard
deviation; TSAT, transferrin saturation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; spKTV, single pool (sp) Kt ⁄V.
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between AHI and PLMI in the Tx group, and no association
was detected in the dialysed group. This could possibly be
explained by the potential disease-modifying effect of ura-
emia. The association between PLMI and the Framingham
scores remained significant even after adjusting for AHI in
addition to other important covariables in the multivariable
models. Importantly, these findings suggest that PLMS is not
simply a marker of OSA in this patient population, and it may
carry an independent cardiovascular risk component in
transplant and dialysed patients. In our study, sleep macro-
structure was similar in patients with versus without PLMS
similar to the epidemiological study by Scofield et al. (2008),
which involved the most patients to date.
Only limited information has been published about the
epidemiology of PLMS in patients on chronic haemodialysis
(Hanly et al., 2003; Jurado-Gamez et al., 2007; Rijsman
et al., 2004). Beecroft et al. reported that the PLMI was
decreased significantly after transplantation in a substantial
proportion of the patients (Beecroft et al., 2008). We also
found a trend towards different prevalence of PLMS in the Tx
and WL groups, but this difference did not reach statistical
significance. It is possible that this is due to the relatively low
power of our analysis. In the study by Beecroft et al. PLMS
improved in all patients after transplantation. It is possible
that more severe PLMS improves more significantly with
transplantation, while less severe PLMS may not change.
This assumption is compatible with our results, as we also
found that severe PLMS was twice as frequent in dialysed
patients as in the Tx group. The main difference between our
study and that by Beecroft and colleagues is that our patients
had a longer median transplantation vintage (66 months
versus 5 months). A potential explanation for the observed
difference could be that PLMS improves immediately after
transplantation, but the disorder gradually returns subse-
quently, as has been suggested previously for restless legs
syndrome (Winkelmann et al., 2002). Importantly, however,
transplant vintage was not associated with the severity of
PLMS in our sample.
Although previous studies did not show an association
between PLMS and age in ESRD populations (Benz et al.,
Table 4 Binary logistic regression model in the total population
[dependent variable: severe periodic limb movements in sleep
(PLMS)]
Odds
ratio (OR)
95%
Confidence
interval
for OR
P-valueLower Upper
Gender (male) 15.302 3.084 75.932 0.001
Age (1-year increase) 1.046 1.001 1.094 0.047
Diabetes (presence) 0.395 0.113 1.384 0.147
BMI (1 kg m)2 increase) 1.022 0.906 1.152 0.723
Current smoker (smoker) 3.916 1.035 14.828 0.044
Type of renal replacement
therapy (dialysis)
4.113 1.265 13.489 0.019
Presence of iron deficiency
(TSAT <20% and ⁄ or
ferritin < 100 lg L)1) (%)
2.558 0.873 7.463 0.087
Apneoa–hypopnoea index
(1 event h)1 decrease)
0.902 0.961 1.023 0.602
Nagelkerke R = 0.388. BMI, body mass index; TSAT, transferrin
saturation.
Waitlisted dialysis patients Waitlisted dialysis patients
Transplanted patients Transplanted patients
(a) (b)
(d)(c)
Figure 2. The association of PLMI and logarithm of Framingham cardiovascular and stroke risk in the waitlisted dialysis (WL) and transplanted
(Tx) populations.
304 A. Lindner et al.
 2011 European Sleep Research Society
2000), the relationship is well documented in the general
population. Increasing age was associated with the presence
of severe PLMS in our sample, which included more dialysed
and transplant patients than previous published studies.
Furthermore, we focused on severe PLMS, and this may
have increased the sensitivity of our analysis. Interestingly,
we found that severe PLMS was associated independently
with male gender. Previous studies did not report gender
differences regarding PLMS among dialysed patients (Benz
et al., 2000; Jurado-Gamez et al., 2007; Parker et al., 2005;
Rijsman et al., 2004). The explanation for this observation is
not immediately obvious. Dialysed patients are generally
older; they have substantially more comorbidities and take
more medications than individuals in the general population.
Some of these factors, or potentially other characteristics
related to uraemia, may contribute to the differences in the
associations observed between dialysed patients compared
to the general population.
To our knowledge, this polysomnographic study has
enrolled the largest sample of Tx and dialysed patients.
Furthermore, we measured a large number of important
sociodemographic and clinical covariables that make our
analyses more reliable. Finally, we enrolled comparable
groups of WL and Tx patients to assess and compare the
epidemiology of PLMS in these patient groups.
Limitations of this report, however, should also be noted.
The cross-sectional design precludes any directional or
causal conclusions. Patients were exclusively Caucasians,
and they were enrolled from a single centre; therefore, our
results are not to be generalized without further consider-
ations. Furthermore, the Framingham risk prediction index
might be skewed in patients with kidney failure. When we
were planning this study there were no available data about
the prevalence of PLMS in Tx population using polysomnog-
raphy, therefore we had little information to use for sample
size considerations. Due to the expensive nature of the
method and the burden it imposes on the patients, feasibility
Table 5 Linear regression model in the total population (depen-
dent variable: logarithm of Framingham cardiovascular risk)
B Beta
95%
Confidence
interval for B
P-valueLower Upper
PLMI
(1 h)1
increase)
0.007 0.222 0.002 0.012 0.004
Type of renal
replacement
therapy
(transplantation)
0.511 0.227 0.109 0.913 0.013
Haemoglobin
(1 g L)1 increase)
0.002 0.033 )0.008 0.011 0.703
Albumin
(1 g L)1 decrease)
0.066 0.253 0.025 0.107 0.002
Gender (male) 0.531 0.271 0.218 0.844 0.001
AHI (1 event h)1
increase)
0.013 0.197 0.003 0.023 0.010
Charlson
Comorbidity
Index (1 increase)
0.155 0.245 0.061 0.249 0.001
Adjusted R2: 0.356. AHI, apnoea–hypopnoea index; PLMI,
Periodic Limb Movement in Sleep Index.
Table 6 Linear regression model in the waitlisted dialysis (WL)
group (dependent variable: logarithm of Framingham cardiovas-
cular risk)
B Beta
95%
Confidence
interval for B
P-valueLower Upper
PLMI
(1 h)1 increase)
0.009 0.357 0.002 0.016 0.015
AHI
(1 event h)1
increase)
0.027 0.343 0.002 0.051 0.034
Haemoglobin
(1 g L)1
decrease)
0.001 0.015 )0.020 0.022 0.917
Albumin
(1 g L)1
decrease)
0.041 0.148 )0.059 0.141 0.411
Charlson
Comorbidity
Index (1 increase)
0.182 0.296 0.003 0.361 0.046
Gender (male) 1.059 0.492 0.339 1.779 0.006
Adjusted R2: 0.488. AHI, apnoea–hypopnoea index; PLMI,
Periodic Limb Movement in Sleep Index.
Table 7 Linear regression model in the transplanted (Tx) group
(dependent variable: logarithm of Framingham cardiovascular risk)
B Beta
95%
Confidence
interval for B
P-valueLower Upper
PLMI
(1 h)1 increase)
0.006 0.157 0.000 0.013 0.090
AHI
(1 event h)1
increase)
0.011 0.178 0.000 0.022 0.058
Haemoglobin
(1 g L)1
increase)
0.005 0.090 )0.006 0.016 0.378
Albumin
(1 g L)1
decrease)
0.086 0.318 0.038 0.135 0.001
Charlson
Comorbidity
Index (1 increase)
0.140 0.212 0.024 0.255 0.018
Gender (male) 0.350 0.188 )0.037 0.738 0.076
Adjusted R2: 0.294. AHI, apnoea–hypopnoea index; PLMI,
Periodic Limb Movement in Sleep Index.
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was a major concern. This study had power to detect a 25%
difference in the prevalence of PLMS (90% power) between
the WL and Tx groups. To detect 15% difference with
90% power, approximately 500 patients would have been
necessary.
Finally, a substantial proportion of both WL and Tx patients
declined to participate. We cannot rule out that symptomatic
patients were more likely to accept the burden of polysom-
nography, whereas good sleepers may have opted to avoid
this test. This type of selection bias affects all studies of sleep
disorders based on polysomnography, and refusal rate was
similar in other studies using PSG in the ESRD population
(Unruh et al., 2006). Although we did not find any difference
between participants and non-participants, it is therefore
unlikely that the high refusal rate would have distorted our
results significantly; the bias that might have been caused by
refusal cannot be ruled out completely. This potential bias,
however, does not invalidate our findings about the associ-
ation between PLMS and increased cardio- and cerebrovas-
cular risk in the Tx population.
In our cross-sectional study we found an independent
association between the severity of PLMS (PLMI) and the risk
of cardiovascular and cerebrovascular disease. Furthermore,
we found that severe PLMS is less frequent in stable prevalent
kidney transplant recipients compared to WL dialysis patients.
Further studies are needed to analyse the association between
PLMS and cardio- and cerebrovascular morbidity in the
general population to analyse if PLMS is also an independent
risk factor for stroke and cardiovascular disease.
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